Recombinant biologics for treatment of bleeding disorders (Q35852300)

10 August 2017

1 reference

title

Recombinant biologics for treatment of bleeding disorders (English)

1 reference

10 August 2017

Paul Bishop

1

1 reference

PubMed ID

15286735

10 August 2017

Jeff Lawson

series ordinal

2

1 reference

10 August 2017

1 August 2004

1 reference

Nature Reviews Drug Discovery

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

684-694

1 reference

10 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1443

10 August 2017

0 references

cites work

Hemophilia in the Talmud and Rabbinic Writings

1 reference

The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII.

21 January 2018

1 reference

Effects of blood product storage protectants on blood coagulation

21 January 2018

1 reference

Blood collection and transfusion in the United States in 1997

31 March 2020

1 reference

The annual cost of blood transfusions in the UK.

31 March 2020

1 reference

Cleavage requirements for activation of factor V by factor Xa

31 March 2020

1 reference

Activation of porcine factor VIII:C by thrombin and factor Xa.

31 March 2020

1 reference

Blood coagulation factor XIII: structure and function

31 March 2020

1 reference

Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures

31 March 2020

1 reference

Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin

31 March 2020

1 reference

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

31 March 2020

1 reference

TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex

31 March 2020

1 reference

Challenges for providing effective hemostasis in surgery and trauma

31 March 2020

1 reference

31 March 2020

THE ROYAL HEMOPHILIA.

1 reference

HEMOPHILIA. II. SOME PROPERTIES OF A SUBSTANCE OBTAINED FROM NORMAL HUMAN PLASMA EFFECTIVE IN ACCELERATING THE COAGULATION OF HEMOPHILIC BLOOD.

31 March 2020

1 reference

A review of the therapeutic uses of thrombin.

31 March 2020

1 reference

Commercial fibrin sealants in surgical care

31 March 2020

1 reference

Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin

31 March 2020

1 reference

Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose

31 March 2020

1 reference

Haemophilia 2002: emerging risks of treatment

31 March 2020

1 reference

The effect of factor XIII on bleeding in coronary surgery

31 March 2020

1 reference

Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease

31 March 2020

1 reference

Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers

31 March 2020

1 reference

Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut

31 March 2020

1 reference

Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group

31 March 2020

1 reference

Allogeneic transfusion risks in the surgical patient.

31 March 2020

1 reference

Transfusion medicine. First of two parts--blood transfusion

31 March 2020

1 reference

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group

31 March 2020

1 reference

Anemia and blood transfusion in critically ill patients.

31 March 2020

1 reference

Effect of blood transfusion on long-term survival after cardiac operation

31 March 2020

1 reference

Platelet activity of high-dose factor VIIa is independent of tissue factor

31 March 2020

1 reference

The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.

31 March 2020

1 reference

Mechanism of factor VIIa-dependent coagulation in hemophilia blood

31 March 2020

1 reference

New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa

31 March 2020

1 reference

The future of recombinant coagulation factors.

31 March 2020

1 reference

Molecular cloning of a cDNA encoding human antihaemophilic factor

31 March 2020

1 reference

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

31 March 2020

1 reference

Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study

31 March 2020

1 reference

Recombinant clotting factors: a review of current clinical status

31 March 2020

1 reference

Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.

31 March 2020

1 reference

Isolation and characterization of a cDNA coding for human factor IX

31 March 2020

1 reference

Characterization of a cDNA coding for human factor VII

31 March 2020

1 reference

Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation

31 March 2020

1 reference

Dosing with recombinant factor viia based on current evidence

31 March 2020

1 reference

Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae

31 March 2020

1 reference

Cloning of fibrinogen genes and their cDNA.

31 March 2020

1 reference

High-level expression of recombinant human fibrinogen in the milk of transgenic mice.

31 March 2020

1 reference

Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease

31 March 2020

1 reference

Recombinant von Willebrand factor: preclinical development

31 March 2020

1 reference

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

31 March 2020

1 reference

Gene therapy for haemophilia.

31 March 2020

1 reference

Clinical gene therapy for nonmalignant disease

31 March 2020

1 reference

Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization

31 March 2020

1 reference

The manufacturing process for B-domain deleted recombinant factor VIII

31 March 2020

1 reference

Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets

31 March 2020

1 reference

Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells

31 March 2020

1 reference

Hemophilia: treatment options in the twenty-first century

31 March 2020

1 reference

Gene therapy ethics and haemophilia: an inevitable therapeutic future?

31 March 2020

1 reference

WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

31 March 2020

1 reference

AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

31 March 2020

1 reference

What is all that thrombin for?

31 March 2020

1 reference

Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation

31 March 2020

1 reference

Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III.

31 March 2020

1 reference

Models of blood coagulation.

31 March 2020

1 reference

Biochemistry and Physiology of Blood Coagulation

31 March 2020

1 reference

Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1443

1 reference

10 August 2017

1 reference

PubMed ID

15286735